VK2809 THR-Beta: VOYAGE Phase 2b 52-Week MASH Results
Viking's VK2809: oral liver-targeted THR-beta agonist. VOYAGE Phase 2b 52-week MASH resolution up to 75%, MRI-PDFF median -55%. 2nd-gen after Resmetirom.
Introduction: The "Next THR-Beta" After Resmetirom (Rezdiffra)
In March 2024, Madrigal's Resmetirom (Rezdiffra) became the first FDA-approved (accelerated approval) drug for MASH[1], establishing the liver-selective thyroid hormone receptor-beta (THR-β) agonist class as clinically validated. The open question for 2026 is how much clinically meaningful differentiation a second-generation THR-β agent can deliver beyond Resmetirom.
The leading candidate is VK2809, an oral THR-β agonist developed by Viking Therapeutics (San Diego, CA). Its Phase 2b VOYAGE trial (NCT04173065; ClinicalTrials.gov actual enrollment 248, Viking safety population 246) 52-week histology readout was presented at AASLD's The Liver Meeting 2024 (November 19, 2024), showing positive results for both MASH resolution and fibrosis improvement[2]. This article reviews the compound profile, clinical data, head-to-head considerations against Resmetirom, and development outlook based on public sources.
1. Compound Profile
| Attribute | Detail |
|---|---|
| INN / generic name | Not assigned / publicly confirmed (VK2809 is the development code) |
| Development codes | VK2809 (formerly MB07811) |
| Sponsor | Viking Therapeutics, Inc. (San Diego, California) |
| Origination & licensing chain | Discovered at Metabasis Therapeutics → Acquired by Ligand Pharmaceuticals in 2009 → Licensed exclusively worldwide to Viking Therapeutics on May 21, 2014[3] |
| Modality | Oral small-molecule, liver-targeted THR-β agonist using HepDirect™ prodrug technology (activated intrahepatically by CYP3A4) |
| Indication | MASH (formerly NASH) / hyperlipidemia |
| Status | Phase 2b VOYAGE (NCT04173065) Completed (52-week final reported Nov 2024). Phase 3 start timing not publicly disclosed |
| Milestones to Ligand | $10M at Phase 3 initiation + up to $225M dev/regulatory + 3.5–7.5% royalty on net sales |
VK2809's distinctive design feature is the HepDirect™ prodrug technology developed at Metabasis: the prodrug crosses the portal circulation and is converted to its active form intracellularly by hepatic CYP3A4, minimizing systemic exposure. This contrasts with Resmetirom, which is a systemically active THR-β-selective compound. The intent is to further reduce off-target THR-α activation in the heart and bone.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Therapeutic Hypothesis: Liver-Selective THR-β Activation
Hepatic THR-β regulates lipid metabolism, mitochondrial β-oxidation, and cholesterol clearance. In MASH, intrahepatic thyroid hormone signaling is reduced. Selective THR-β activation is hypothesized to deliver:
- Reduced hepatic lipid burden: suppression of de novo lipogenesis and enhanced β-oxidation
- Lowered LDL-C: induction of CYP7A1, accelerating bile acid synthesis and cholesterol clearance
- Indirect fibrosis improvement: reduced hepatocyte stress secondary to lipid normalization
Avoiding THR-α (cardiac, skeletal) activation prevents the tachycardia and bone-density loss that historically derailed systemic thyroid hormone replacement strategies for MASH[4].
3. VOYAGE Phase 2b Design
| Parameter | Detail |
|---|---|
| Trial number | NCT04173065 |
| Design | Phase 2b, randomized, double-blind, placebo-controlled, multicenter, international |
| Patients | Biopsy-confirmed MASH, F2-F3 fibrosis (with limited F1B + metabolic risk factors), MRI-PDFF ≥8% |
| Sample size | ClinicalTrials.gov actual enrollment 248 (Viking safety population n=246) |
| Doses | Oral. 1 mg QD, 2.5 mg QD, 5 mg QOD, and 10 mg QOD (mixed dose/frequency design) |
| Primary endpoint | Relative change in MRI-PDFF at week 12 |
| Histology secondary endpoints | Week 52 MASH resolution (no fibrosis worsening), ≥1-stage fibrosis improvement (no MASH worsening), liver enzymes, lipid panel |
4. VOYAGE 52-Week Results (AASLD 2024)
VOYAGE met both the primary endpoint (week 12 MRI-PDFF) and the histology secondary endpoints (week 52 biopsy)[2].
4.1 MRI-PDFF (Week 12, Primary EP)
- The main VK2809 dose groups showed significant hepatic fat reduction (1 mg QD did not reach significance in the primary analysis)
- Median relative change: 38–55% reduction from baseline vs -8.0% placebo (Viking pipeline-page value for the 12-week primary endpoint)
- On the MASH-resolution secondary analysis, the pooled VK2809 group reached p<0.0001 (p<0.05 per dose group)
4.2 Week 52 Histology Outcomes (Secondary EPs)
Numbers differ by analysis population. The headline analysis (patients with baseline/post-baseline MRI and a Week 52 biopsy) and a conservative sensitivity analysis (missing data imputed as non-response) are shown separately.
Headline analysis (completer-like)
| Parameter | VK2809 (dose-group range / pooled) | Placebo |
|---|---|---|
| MASH resolution (no fibrosis worsening) | 63–75% (pooled 69%; ~75% at top dose) | 29% |
| ≥1-stage fibrosis improvement (no MASH worsening) | 44–57% (pooled 51%; significant at top 2 doses, 5 mg & 10 mg QOD) | 34% |
| Both endpoints (resolution + fibrosis improvement) | 40–50% (pooled 44%) | 20% |
Sensitivity analysis (missing = non-response)
| Parameter | VK2809 (dose-group range / pooled) | Placebo |
|---|---|---|
| MASH resolution | 47–59% (pooled 56%) | 21% |
| ≥1-stage fibrosis improvement | 39–47% (pooled 42%) | 25% |
| Both endpoints | 31–41% (pooled 36%) | 14% |
4.3 Safety / Tolerability
- Good GI tolerability across the 52-week treatment window (no significant excess of diarrhea or nausea over placebo)
- No reported serious THR-α-mediated adverse events (tachycardia, atrial fibrillation, bone-density loss)
- AASLD 2024's primary safety message: "tolerability profile compatible with chronic dosing"
Note (nature of the source): The primary basis for these numbers is Viking's press releases and the AASLD 2024 abstract (Gastroenterology & Hepatology (N Y) highlights supplement; the PubMed record lists "No authors listed," with Lian B and colleagues as presenters)[2]. A full peer-reviewed publication (NEJM, Lancet, JHEP) was not available as of April 2026, so the figures here should be read as company/abstract-level data.
5. Class Comparison: VK2809 vs Resmetirom (Rezdiffra)
| Axis | Resmetirom (Madrigal, Rezdiffra) | VK2809 (Viking Therapeutics) |
|---|---|---|
| Approval / development | March 2024 FDA accelerated approval (F2-F3 MASH)[1] | Phase 2b complete; Phase 3 start timing not publicly disclosed |
| Route / frequency | Oral, once daily, 80 or 100 mg | Oral, 1 mg & 2.5 mg QD / 5 mg & 10 mg QOD (mixed design) |
| Design concept | Systemic THR-β-selective (β/α ~28×) | Liver-targeted prodrug (HepDirect™) |
| Phase 3 scale | MAESTRO-NASH (n=966, Harrison 2024 NEJM[1]) | Phase 3 not yet initiated |
| MASH resolution (high dose) | 26% (80 mg) / 30% (100 mg) vs 10% placebo | 63–75% vs 29% placebo (VOYAGE week 52 headline analysis) |
| ≥1-stage fibrosis improvement | 24% (80 mg) / 26% (100 mg) vs 14% placebo | 44–57% vs 34% placebo (headline analysis) |
| MRI-PDFF reduction (week 12 primary) | -32% (80 mg) / -37% (100 mg) vs -10% placebo | median 38–55% reduction (vs -8% placebo) |
Caveats: VOYAGE secondary EP numbers appear to exceed MAESTRO-NASH on headline figures alone, but direct comparison is not valid because:
- Trial size differs by ~4× (VOYAGE n=248 vs MAESTRO-NASH n=966)
- Fibrosis stage distribution: VOYAGE included F2-F3 + a limited F1B fraction; MAESTRO-NASH included F1B-F3
- Adjudication standards: MAESTRO-NASH used NASH CRN central two-reader consensus; VOYAGE design is similar but only abstract-level disclosure
- Same 52-week observation window for both
A meaningful comparison will require VOYAGE 52-week peer-reviewed full publication and a VK2809 Phase 3 design adopting MAESTRO-NASH-style central adjudication.
6. Phase 3 Outlook and Pipeline Allocation Risk
In 2025–2026, Viking's operational focus has shifted heavily toward VK2735 (oral/SC GLP-1/GIP dual agonist for obesity)[5]. Phase 3 VANQUISH-1 enrollment completed November 19, 2025; VANQUISH-2 enrollment completed March 26, 2026.
VK2809 Phase 3 timing is not formally fixed. Viking's Q1 2026 corporate update foregrounds VK2735 Phase 3 progress while describing VK2809 only as having met its Phase 2b primary and secondary endpoints; any reference to Phase 3 or approval timing in this article is the author's outlook, not official guidance. Given Resmetirom's healthy market launch, VK2809's Phase 3 must demonstrate clinical differentiation (higher MASH resolution rates and/or earlier fibrosis improvement) to win second-line market share.
License Dispute Risk (Ligand)
On April 24, 2026, Ligand Pharmaceuticals issued notice purporting to terminate the TR-Beta Program license (under the 2014 Master License Agreement), with VK2809 and VK0214 included in that program — disclosed in Viking's Q1 2026 Form 10-Q and Ligand's SEC filing[7]. Ligand alleges Viking breached its obligation to use commercially reasonable efforts to develop the program; Viking states that Ligand has no right to terminate under the agreement and will vigorously defend its rights. Because the dispute bears directly on VK2809's development, partnering, and commercialization, evaluating Phase 3 timing or partnership scenarios requires watching the license dispute outcome alongside the clinical data.
7. Competitive Positioning Across MASH Pipeline
Across the non-hormonal classes (FGF21, GLP-1, PPAR, FASN), VK2809 aims to combine liver-fat reduction, fibrosis improvement, and LDL-C lowering in a single agent:
- FGF21 class: Efruxifermin (Akero/Novo), Pegozafermin (89bio/Roche)
- GLP-1 / GLP-1 combos: Semaglutide ESSENCE[6], Survodutide
- panPPAR: Lanifibranor
- FASN: Denifanstat
- THR-β (first-in-class): Resmetirom (Madrigal, approved)
VK2809's open question is whether Phase 3 can show differentiation as a Resmetirom successor (e.g., MRI-PDFF reduction magnitude and MASH resolution rates). If hard endpoints (cirrhosis progression, liver-related mortality) show class equivalence, the first-mover Resmetirom may retain its advantage. Note also that by 2026 the competitive field has shifted — Wegovy (semaglutide) has a MASH approval, and FGF21 and GLP-1/GIP combinations are advancing. See the full landscape in MASH Drug Landscape 2025.
8. FAQ
Q1. Is VK2809 actually more effective than Resmetirom?
A. VOYAGE secondary EP MASH-resolution headline numbers (63–75%) appear higher than MAESTRO-NASH (26–30%), but direct comparison is invalid because of differences in sample size (248 vs 966), fibrosis stage distribution, adjudication standards, and analysis population (headline vs missing-imputed sensitivity analysis). Final answer must wait for VK2809 Phase 3.
Q2. What does "liver-selective" mean for VK2809?
A. The HepDirect™ prodrug is designed to be taken up via the portal circulation and converted to its active form by hepatic CYP3A4, keeping systemic active-drug levels low. This theoretically reduces THR-α-mediated cardiac (tachycardia) and skeletal (bone-density loss) liabilities.
Q3. When could VK2809 be approved?
A. As of April 2026, Phase 3 has not started and Phase 3 start timing is not publicly disclosed. Approval timing depends on Phase 3 initiation, trial duration, and review — any specific year is the author's estimate, not official guidance. The Ligand license dispute may also affect development pace.
Q4. How does VK2735 (obesity) relate to VK2809?
A. Both are flagship Viking assets with different mechanisms and indications. VK2735 is a SC/oral GLP-1/GIP dual agonist for obesity (Phase 3 VANQUISH); VK2809 is THR-β agonist for MASH (Phase 2b VOYAGE). Viking's 2025–2026 resource allocation has shifted heavily toward VK2735, which constrains VK2809 Phase 3 timing.
Q5. Will VK2809 Phase 3 be designed for direct comparison with MAESTRO-NASH?
A. FDA approval for MASH typically requires NASH CRN central adjudication packages (MASH resolution and/or ≥1-stage fibrosis improvement, both without worsening of the other). If VK2809 Phase 3 adopts a MAESTRO-NASH-like design, the 2027–2028 timeframe could yield directly comparable head-to-head data packages.
9. Conclusion: A Realistic Win Path for the Resmetirom Successor
VK2809's edge is its HepDirect™ liver-targeting design combined with VOYAGE 52-week headline MASH resolution rates of 63–75%, positioning it as one of the most advanced public datasets among Resmetirom-successor THR-β candidates. However:
- Phase 3 has not started; start and approval timing are not publicly disclosed (the years cited here are the author's estimate)
- Viking's resources are heavily committed to VK2735 (obesity), constraining development pace
- A Ligand license dispute may affect development and partnering
- No head-to-head data exist; proving class superiority depends on Phase 3 design
Competing Phase 3 datasets may cluster in the late 2020s, and VK2809's position will depend on how much it can differentiate as a follow-on THR-β. From a non-invasive biomarker standpoint, the extent to which VK2809 Phase 3 incorporates FIB-4, ELF score, and PRO-C3 will materially affect both regulatory and commercial trajectory.
References
[1] Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PMID: 38324483
[2] Lian B, et al. Results From the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients With Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial. Gastroenterol Hepatol (N Y). 2024;20(12 Suppl 11):13-14. PMID: 39896964
[3] Viking Therapeutics, SEC 10-K filing 2015 / Master License Agreement (Ligand Pharmaceuticals, executed 2014-05-21, amended 2014-09-06 and 2015-04-08). Worldwide TRβ rights for VK2809 and VK0214.
[4] Harrison SA, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012-2024. PMID: 31727409
[5] Viking Therapeutics, Press Releases. "Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735" (2025-11-19) / "VANQUISH-2 Trial" (2026-03-26).
[6] Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. PMID: 40305708
[7] Ligand Pharmaceuticals Inc., Form 8-K (April 24, 2026; notice purporting to terminate the TR-Beta Program license with Viking Therapeutics). U.S. SEC EDGAR. Filing / Viking Therapeutics, Inc., Form 10-Q for Q1 2026 (disclosure of the TR-Beta Program license dispute).
Related Articles
- Resmetirom (Rezdiffra): First MASH Approval
- Resmetirom Clinical Detail: MAESTRO-NASH/MAESTRO-NASH-OUTCOMES
- MASH Drug Landscape 2025
- Efruxifermin (FGF21): HARMONY/SYMMETRY
- Pegozafermin (FGF21 analog)
- Lanifibranor (panPPAR): NATiV3
- Denifanstat (FASN): FASCINATE-2
- Semaglutide ESSENCE Phase 3
- MASH Drug Future Landscape
- FIB-4 Score Complete Guide
- PRO-C3: MASH Treatment Response Marker